Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Nitromethylthiobenzene derivatives as aldose reductase inhibitors

Oct. 19, 1998

Bristol-Myers Squibb discloses novel MTP inhibitors

Oct. 19, 1998

Orquest seeks European marketing clearance for Healos

Oct. 19, 1998

Amgen expands calcimimetic drug development

Oct. 19, 1998

Alliance decisively moves ahead with development of blood substitute

Oct. 19, 1998

Hemosol successfully completes U.K. Hemolink trial

Oct. 16, 1998

New treatment option now available for type II diabetics in the U.K.

Oct. 16, 1998

Phase I trials to begin with vomeropherin compound for PMS

Oct. 15, 1998

Pharming and Genzyme form joint venture to develop enzyme for Pompe's disease

Oct. 15, 1998

U.K. launch announced for Evista

Oct. 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...